✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Mercury Laboratories Ltd.

MERCURYLAB

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹102 Cr.
P/E
20.71

Mercury Laboratories Ltd.

  • Mercury Laboratories
  • Aptus Pharma
  • Mangalam Drugs&Org.

FAQs on Mercury Laboratories Ltd. Shareprice

Mercury Laboratories has given better returns compared to its competitors.
Mercury Laboratories has grown at ~-8.16% over the last 1yrs while peers have grown at a median rate of -39.05%

Mercury Laboratories is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Mercury Laboratories is 20.71, while 3 year average PE is 20.96.
Also latest EV/EBITDA of Mercury Laboratories is 12.1 while 3yr average is 11.57.

View FAQ's On Business

Growth Table

  • Mercury Laboratories Ltd.
  • Aptus Pharma
  • Mangalam Drugs&Org.

Balance Sheet

  • Mercury Laboratories Ltd.
  • Aptus Pharma
  • Mangalam Drugs&Org.

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Mercury Laboratories Ltd.
  • Aptus Pharma
  • Mangalam Drugs&Org.

Cash Flow

  • Mercury Laboratories Ltd.
  • Aptus Pharma
  • Mangalam Drugs&Org.

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Mercury Laboratories Ltd.
  • Aptus Pharma
  • Mangalam Drugs&Org.

Quarterly Results

  • Mercury Laboratories Ltd.
  • Aptus Pharma
  • Mangalam Drugs&Org.

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Mercury Laboratories Ltd. Financials

Balance sheet of Mercury Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Mercury Laboratories is increasing.
Latest net debt of Mercury Laboratories is ₹1.82 Crs as of Sep-25.
This is greater than Mar-25 when it was -₹0.29 Crs.

The profit is oscillating.
The profit of Mercury Laboratories is ₹4.91 Crs for TTM, ₹3.14 Crs for Mar 2025 and ₹5.65 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Mercury Laboratories latest dividend payout ratio is 13.36% and 3yr average dividend payout ratio is 9.44%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech